Application of a sheep milk casein-derived bioactive peptide

By extracting GPF and VPPF bioactive peptides from sheep milk casein and verifying their interaction with α-glucosidase using various techniques, the problem of bioactive peptide screening in existing technologies has been solved, achieving effective regulation of carbohydrate digestion and postprandial blood glucose control, and providing a high-value utilization pathway for sheep milk protein resources.

CN123100837APending Publication Date: 2026-11-17SHANXI YOULISHI DAIRY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611447186.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-17
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies make it difficult to effectively screen for bioactive peptides with clear structural features and functional activities from sheep milk casein, and existing α-glucosidase inhibitors have side effects and cannot effectively regulate the carbohydrate digestion process.

Method used

Two bioactive peptides, GPF and VPPF, were extracted from sheep milk casein using enzymatic hydrolysis and ultrafiltration fractionation techniques. By combining molecular docking, fluorescence quenching, isothermal titration calorimetry, and atomic force microscopy, their interaction with α-glucosidase was verified, and bioactive peptides with different inhibition modes were screened out for use in regulating carbohydrate digestion.

Benefits of technology

GPF and VPPF exhibit excellent α-glucosidase inhibitory activity, which can delay glucose release during in vitro starch digestion, reduce starch digestion rate, and significantly reduce postprandial blood glucose response in vivo, providing natural and safe functional food active ingredients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123100837A_ABST
    Figure CN123100837A_ABST
Patent Text Reader

Abstract

This application discloses the application of an active peptide derived from sheep milk casein. The active peptide is obtained by enzymatic hydrolysis of sheep milk casein with proteases, and includes GPF and VPPF. The active peptide exhibits good α-glucosidase inhibitory activity and displays different enzyme inhibition modes. It can delay glucose release during in vitro starch digestion, reduce the starch digestion rate and final degree of digestion, demonstrating potential application value in regulating carbohydrate digestion. The active peptide from sheep milk casein provided by this invention is naturally sourced, has a simple preparation method, and has the potential to be used as an active ingredient in functional foods, providing a new technical approach for the high-value utilization of sheep milk protein resources.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of food biotechnology, specifically to the application of an active peptide derived from sheep milk casein. Background Technology

[0002] With changing lifestyles, the incidence of metabolic diseases such as diabetes is gradually increasing, making postprandial blood glucose regulation a crucial aspect of blood glucose management. After dietary carbohydrates such as starch enter the body, they need to be converted into glucose through the gradual action of digestive enzymes. Alpha-glucosidase participates in the hydrolysis of terminal glycosidic bonds and is closely related to postprandial blood glucose elevation. In existing technologies, alpha-glucosidase inhibitors such as acarbose can reduce the rate of glucose release by delaying carbohydrate digestion, but long-term use may cause side effects such as gastrointestinal discomfort. Therefore, the development of natural active ingredients derived from food ingredients as alpha-glucosidase regulators has attracted attention.

[0003] Milk proteins are an important source for the preparation of bioactive peptides. Enzymatic hydrolysis of proteins can release short peptides with different biological activities. Related studies have shown that milk-derived bioactive peptides play certain roles in antioxidation, blood pressure reduction, and enzyme activity regulation. Casein, as an important component of milk proteins, contains abundant potentially bioactive peptide sequences and is an important precursor for the development of functional bioactive peptides. Currently, research on milk-derived bioactive peptides mainly focuses on bovine milk proteins and whey proteins, while the potential functional bioactive peptides of sheep milk casein, as a milk protein resource with a unique protein composition, still await further development.

[0004] In existing technologies, studies on the activity of sheep milk casein mostly employ protease hydrolysis to obtain hydrolysates, and then analyze their functional properties through in vitro activity evaluation. However, due to the different cleavage specificities of proteases, different hydrolysis methods lead to variations in the peptide composition and activity of the hydrolysates, making it difficult to fully release highly active target peptides using a single hydrolysis method. Furthermore, the composition of sheep milk casein protease hydrolysates is complex, making it difficult to identify the key active peptides that exert their effects solely through overall activity evaluation.

[0005] Furthermore, most existing research on bioactive peptides from milk sources focuses on activity evaluation, while studies on the binding modes, inhibition types, and mechanisms of action between specific peptides obtained through screening and target enzymes remain insufficient. Therefore, how to obtain target peptides with clear structural characteristics and functional activities from sheep milk casein, and further clarify their functional characteristics, is a problem that needs to be solved in the development and utilization of sheep milk casein resources. Summary of the Invention

[0006] To address the problems in the prior art, this application provides an application of sheep milk casein-derived bioactive peptides in regulating carbohydrate digestion. The sheep milk casein-derived bioactive peptides include GPF and VPPF. The structure of GPF is shown in sequence 1, and the structure of VPPF is shown in sequence 2, wherein Sequence 1: Gly-Pro-Phe, and Sequence 2: Val-Pro-Pro-Phe.

[0007] Beneficial effects

[0008] The bioactive peptides described in this application exhibit good α-glucosidase inhibitory activity and demonstrate different enzyme inhibition modes. Analysis using enzyme inhibition kinetics, molecular docking, isothermal titration calorimetry, fluorescence quenching, and atomic force microscopy shows that the bioactive peptides can interact with α-glucosidase, affecting the enzyme's molecular microenvironment and structural state, thereby reducing the enzyme's catalytic activity. Furthermore, the bioactive peptides can delay glucose release during in vitro starch digestion, reducing the starch digestion rate and final degree of digestion, demonstrating potential application value in regulating carbohydrate digestion. The bioactive peptides derived from sheep milk casein provided by this invention are naturally sourced, have a simple preparation method, and possess application potential as active ingredients in functional foods, providing a new technical approach for the high-value utilization of sheep milk protein resources.

[0009] Compared with the prior art, the active peptides derived from sheep milk casein and their preparation method provided by the present invention have the following beneficial effects:

[0010] (1) The active peptides GPF and VPPF provided by this invention have good α-glucosidase inhibitory activity. Among them, VPPF shows a better inhibitory effect, with a half-maximal inhibitory concentration (IC50) of 100%. The concentration of α-glucosidase was 4.236 ± 0.829 mg / mL, which was significantly lower than that of GPF (13.570 ± 3.390 mg / mL), indicating that the active peptide can effectively reduce the catalytic activity of α-glucosidase and provide a natural active ingredient derived from food protein for regulating the carbohydrate digestion process.

[0011] (2) The bioactive peptides of this invention possess enzyme regulatory characteristics that differ from traditional single-inhibition modes. Specifically, VPPF primarily exhibits competitive inhibition, binding to free α-glucosidase and affecting the binding of substrate to the enzyme's active site; GPF exhibits anti-competitive inhibition, binding to the enzyme-substrate complex and reducing catalytic efficiency. These two bioactive peptides regulate enzyme activity through different modes of action, enriching the mechanism of action of sheep milk-derived bioactive peptides in regulating carbohydrate digestion.

[0012] (3) This invention combines multiple techniques, including molecular docking, fluorescence quenching, isothermal titration (ITC), and atomic force microscopy (AFM), to verify the interaction between active peptides and α-glucosidase from multiple levels, including molecular binding, thermodynamic properties, and structural changes. The results show that GPF and VPPF can bind to α-glucosidase through hydrogen bonds, hydrophobic interactions, and other non-covalent interactions, causing changes in the fluorescence microenvironment of the enzyme molecule and affecting the protein surface morphology and structural state. Among them, VPPF exhibits a higher binding affinity, indicating that its strong inhibitory activity is closely related to the peptide-enzyme binding ability.

[0013] (4) The active peptides provided by this invention can play a regulatory role in complex digestive systems. In an in vitro starch digestion model, both GPF and VPPF can reduce glucose release levels, with VPPF significantly reducing the glucose release rate during the rapid digestion phase. The fact that it slows down the starch hydrolysis process indicates that it can not only inhibit α-glucosidase activity in a single enzyme system, but also play a role in delaying carbohydrate digestion in a simulated digestion environment.

[0014] (5) The present invention further verified the in vivo regulatory effect of the active peptide through animal experiments. Using a starch-loaded mouse model, it was found that VPPF can reduce the rise in blood glucose after starch intake and significantly reduce the area under the blood glucose curve (AUC), indicating that it has potential application value in reducing postprandial blood glucose response.

[0015] (6) The active peptides provided by this invention are derived from natural sheep milk casein, with a wide range of raw material sources and high safety. The preparation process adopts conventional enzymatic hydrolysis, ultrafiltration fractionation and activity screening technology, with mild process conditions and simple operation, which is suitable for the development of functional food ingredients. This invention provides a new technical solution for the high-value utilization of sheep milk protein resources and the development of food active ingredients with the function of regulating carbohydrate digestion. Attached Figure Description

[0016] Figure 1 shows the two oligopeptides. Figure 1, where a is GPF and b is VPPF;

[0017] Figure 2 shows the inhibition kinetics analysis of VPPF (where a is the Lineweaver-Burk plot, b is the Dixon plot, and c is the Cornish-Bowden plot).

[0018] Figure 3 shows the inhibition kinetics analysis of GPF (where a is the Lineweaver-Burk plot, b is the Dixon plot, and c is the Cornish-Bowden plot);

[0019] Figure 4 shows the fluorescence quenching effect of oligopeptide VPPF on α-glucosidase, where a is the fluorescence spectrum of VPPF mixed with α-glucosidase after subtracting the autofluorescence of VPPF, b is the autofluorescence spectrum of VPPF, and c is the original spectrum of VPPF mixed with α-glucosidase.

[0020] Figure 5 shows the fluorescence quenching effect of oligopeptide GPF on α-glucosidase, where a is the fluorescence spectrum of VPPF mixed with α-glucosidase after subtracting the autofluorescence of GPF, b is the autofluorescence spectrum of GPF, and c is the original spectrum of GPF mixed with α-glucosidase.

[0021] In Figure 6, a is the VPPF Stern–Volmer equation graph, and b is the VPPF double logarithmic equation graph;

[0022] In Figure 7, a is the GPF Stern–Volmer equation graph, and b is the GPF double logarithmic equation graph;

[0023] Figure 8. ITC titration and fitting images of VPPF (a) and GPF (b);

[0024] Figure 9 shows atomic force microscopy images of α-glucosidase alone and in combination with two oligopeptides;

[0025] Figure 10 shows the glucose content change curves and kinetic analysis of starch digestion in vitro, where a is the glucose content change curve of each component during starch digestion in vitro, b is the kinetic analysis of VPPF digestion in vitro, and c is the kinetic analysis of GPF digestion in vitro.

[0026] Figure 11 shows the significance statistical analysis of the rate constant (k1) of the rapid digestion stage and the rate constant (k2) of the slow digestion stage;

[0027] In Figure 12, a represents the comparison of the area under the blood glucose curve (AUC) of each group of mice, and b represents the comparison of the body weight of each group of mice.

[0028] Figure 13 shows the changes in blood glucose levels in mice in each group after starch loading. Detailed Implementation

[0029] The preferred embodiments of the present invention will now be described in detail with reference to specific examples. It should be understood that the following examples are given for illustrative purposes only and are not intended to limit the scope of the invention. Those skilled in the art can make various modifications and substitutions to the present invention without departing from its spirit and essence.

[0030] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0031] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.

[0032] One embodiment of this application provides the application of a sheep milk casein-derived bioactive peptide in regulating carbohydrate digestion. The sheep milk casein-derived bioactive peptide includes GPF and VPPF. The structure of GPF is shown in sequence 1, and the structure of VPPF is shown in sequence 2, wherein Sequence 1: Gly-Pro-Phe, and Sequence 2: Val-Pro-Pro-Phe.

[0033] In one embodiment, the active peptide derived from sheep milk casein regulates the carbohydrate digestion process by delaying glucose release during in vitro starch digestion, thereby reducing the starch digestion rate and the final degree of digestion.

[0034] In one embodiment, the active peptide derived from sheep milk casein has α-glucosidase inhibitory activity.

[0035] In one embodiment, the inhibition of α-glucosidase by VPPF conforms to the characteristics of competitive inhibition, while the inhibition of α-glucosidase by GPF conforms to the characteristics of uncompetitive inhibition.

[0036] Casein extraction:

[0037] Fresh goat milk was centrifuged at 5000 ×g for 15 min at 4 ℃ to remove the supernatant fat and collect the skim milk. The skimming process was repeated twice to ensure complete separation of milk fat. 10% (v / v) hydrochloric acid was slowly added dropwise to the skim milk, and the pH was adjusted to 5.2 under magnetic stirring to allow casein to precipitate completely. The precipitate was then allowed to stand at room temperature for 60 min. Subsequently, it was centrifuged at 5000 ×g for 10 min at 4 ℃, the supernatant was discarded, and the precipitate was collected to obtain goat milk casein. The obtained precipitate was freeze-dried to obtain goat milk casein lyophilized powder, which was stored at -20 ℃ for subsequent enzymatic hydrolysis experiments.

[0038] Enzymatic hydrolysis with different proteases and ultrafiltration fractionation:

[0039] Since different proteases have different enzymatic properties and optimal reaction conditions, in order to ensure that each protease fully exerts its catalytic activity, this invention uses its appropriate enzymatic hydrolysis conditions for enzymatic hydrolysis, and compares the α-glucosidase inhibitory activity of the obtained enzymatic hydrolysis products to screen the optimal enzymatic hydrolysis scheme.

[0040] The prepared sheep milk casein was hydrolyzed using the following enzymatic hydrolysis scheme: papain enzyme dosage was 9000 U / g, hydrolysis temperature was 50 ℃, pH was 7.0, and hydrolysis time was 360 min.

[0041] After enzymatic hydrolysis, the hydrolysate was heated at 100 °C for 15 min to inactivate the enzyme. After cooling to room temperature, it was centrifuged and the supernatant was collected. Subsequently, the supernatant was fractionated using an ultrafiltration membrane to collect fractions with molecular weights greater than 3 kDa, 1–3 kDa, and less than 1 kDa. Each fraction was then freeze-dried for later use.

[0042] Synthesis of bioactive peptides:

[0043] In this embodiment, the active peptides GPF and VPPF were prepared by ChinaPeptides Co., Ltd. (Shanghai, China) using solid-phase peptide synthesis technology. The purity of the obtained peptides was ≥95%, which were used for subsequent determination of α-glucosidase inhibitory activity and half-maximal inhibitory concentration (IC50). ) determination and analysis of peptide-enzyme interaction mechanism.

[0044] Candidate bioactive peptides obtained from enzymatic hydrolysis were chemically synthesized using solid-phase peptide synthesis (SPPS). Specifically, based on the amino acid sequence of the target peptide, an amino acid coupling reaction was performed sequentially using resin as a solid-phase support to elongate the peptide chain. After the reaction, the peptides were deprotected, cleaved, purified, and lyophilized to obtain the target bioactive peptides. The obtained peptides were further purified using high-performance liquid chromatography (HPLC) and their molecular weight was determined by mass spectrometry (MS) to confirm their structural correctness.

[0045] Half-maximal inhibitory concentration (IC50) ) Measurement

[0046] Using half-maximal inhibitory concentration (IC50) The inhibitory activity of candidate active peptides against α-glucosidase was detected. Synthetically synthesized candidate active peptides were prepared into solutions with different concentration gradients (0.1–50 mg / mL). The inhibition rate of the candidate active peptides against α-glucosidase at different concentrations was determined using the following method for α-glucosidase inhibitory activity assay with pNPG as a substrate.

[0047] The inhibitory activity of the samples against α-glucosidase was determined using a substrate consumption method. 20 μL of different concentrations of active peptide solution and 20 μL of α-glucosidase solution (4 U / mL) were added to 48-well plates and pre-incubated at 4 °C for 10 min. Subsequently, 400 μL of 10 mmol / L pNPG solution was added to initiate the reaction, and the enzymatic reaction was carried out at 37 °C. The reaction was terminated by adding 440 μL of 0.3 mol / L Na₂CO₃ solution at 0, 3, 6, and 9 min after the start of the reaction, and the absorbance was immediately measured at 405 nm.

[0048] The initial reaction rate (ΔA / min) was calculated based on the absorbance changes at each time point, and denoted as the reaction rate (v) of the sample group and the reaction rate (v0) of the blank control group, respectively. The α-amylase inhibition rate was calculated according to formula (1):

[0049] (1)

[0050] In the formula, v is the initial reaction rate (ΔA / min) in the presence of the sample, and v0 is the initial reaction rate (ΔA / min) in the control group. The candidate active peptide concentration is plotted on the x-axis (logarithmically transformed), and the α-glucosidase inhibition rate is plotted on the y-axis. A DoseResp nonlinear regression model in Origin 2021 software (OriginLab Corporation, Northampton, MA, USA) is used for fitting, and the half-maximal inhibitory concentration (IC50) of the candidate active peptide is calculated based on the fitted curve. ).

[0051] The fitted equation is as follows:

[0052] (2)

[0053] In the formula, [I] represents the concentration of the candidate active peptide (mg / mL); I represents the α-glucosidase inhibition rate (%) at the corresponding concentration; Imax represents the maximum inhibition rate (%); and HillSlope represents the Hill slope. As shown in Figure 1, the two oligopeptides... picture.

[0054] Results Analysis

[0055] Based on the fitting results, the active peptide VPPF The value was 4.2360±0.8290 mg / ml, indicating the activity of the peptide GPF. The value was 13.5700±3.3930 mg / mL, indicating that both achieved 50% inhibition of enzyme activity at low concentrations, demonstrating good α-glucosidase inhibitory activity. VPPF showed better inhibitory effect on α-glucosidase than GPF.

[0056] Inhibition kinetic analysis

[0057] To elucidate the inhibitory mechanism of the candidate active peptide on α-glucosidase, the initial rate of the enzymatic reaction was determined under different substrate and inhibitor concentrations. Using pNPG as the substrate, four substrate concentrations of 5, 7.5, 10, and 15 mmol / L were set, while the concentration of the candidate active peptide was set from 0 to 30 mg / mL. The initial reaction rate (v) of each reaction system was determined using the α-glucosidase inhibitory activity assay method described in the assay section.

[0058] The experimental data were analyzed using Origin 2021 software. Dixon plots, Cornish–Bowden plots, and Lineweaver–Burk plots were plotted. These three classic enzyme kinetic analysis methods were combined to determine the inhibitory type of α-glucosidase by the candidate active peptides, and the corresponding kinetic parameters were calculated. The kinetic equations used are as follows:

[0059] Dixon equations

[0060] (3)

[0061] Cornish–Bowden equations

[0062] (4)

[0063] Lineweaver–Burk equations

[0064] (5)

[0065] In the formula, v is the initial rate of the enzymatic reaction; Vmax is the maximum reaction rate; Km ​​is the Michaelis constant; a is the substrate concentration (mmol / L); i is the concentration of the candidate active peptide (mg / mL); Kic represents the inhibition constant of the inhibitor binding to the free enzyme; and Kiu represents the inhibition constant of the inhibitor binding to the enzyme-substrate complex. Dixon plots, Cornish–Bowden plots, and Lineweaver–Burk plots were plotted based on experimental data obtained from different substrate and candidate active peptide concentrations. The type of inhibition of the candidate active peptide was determined by the intersection of the fitted lines in each plot. The inhibition kinetics of VPPF are analyzed as follows: Figure 2 As shown in Figure 3, a is the Lineweaver-Burk plot, b is the Dixon plot, and c is the Cornish-Bowden plot; the inhibition kinetics analysis of GPF is shown in Figure 3, where a is the Lineweaver-Burk plot, b is the Dixon plot, and c is the Cornish-Bowden plot.

[0066] Results Analysis

[0067] The inhibition of α-glucosidase by VPPF exhibits competitive inhibition characteristics, while the inhibition of α-glucosidase by GPF exhibits uncompetitive inhibition characteristics.

[0068] Fluorescence quenching analysis

[0069] The interaction between candidate active peptides and α-glucosidase was investigated using fluorescence spectroscopy, and the effect of candidate active peptides on the endogenous fluorescent microenvironment of the enzyme protein was evaluated. Different concentrations of candidate active peptide solutions (0.2–1.0 mg / mL) were prepared. 40 μL of the sample solution was thoroughly mixed with 400 μL of α-glucosidase solution (2 U / mL) and incubated at 4 °C for 30 min.

[0070] After incubation, the mixture was transferred to a quartz cuvette, and the fluorescence emission spectrum was measured using a fluorescence spectrophotometer. The measurement conditions were set as follows: excitation wavelength (λex) 280 nm, emission wavelength (λem) 300–500 nm. The fluorescence spectra of α-glucosidase under different concentrations of candidate active peptides were recorded, with an enzyme solution without candidate active peptides used as a blank control. The results are shown in Figure 4, which illustrates the fluorescence quenching effect of the oligopeptide VPPF on α-glucosidase; and Figure 5, which illustrates the fluorescence quenching effect of the oligopeptide GPF on α-glucosidase.

[0071] The fluorescence quenching behavior of candidate active peptides on α-glucosidase was analyzed using the Stern–Volmer equation, and the fluorescence quenching constant (K) was calculated. FQ The binding constant (Ka) and the bimolecular quenching rate constant (kq) were calculated. Figure 6 shows the VPPF Stern–Volmer equation and the VPPF double logarithmic equation; Figure 7 shows the GPF Stern–Volmer equation and the VPPF double logarithmic equation. Simultaneously, the binding constant (Ka) and the number of binding sites (n) were calculated using the double logarithmic equation to evaluate the binding affinity between the candidate active peptide and α-glucosidase. The equations used are as follows:

[0072] Stern–Volmer equations

[0073] (6)

[0074] Double logarithmic equations

[0075] (7)

[0076] In the formula, F and F represent the maximum fluorescence intensity of α-glucosidase when no candidate active peptide was added and when the candidate active peptide was added, respectively; [Q] represents the concentration of the candidate active peptide (mg / mL); The average lifetime of the fluorescent group is taken as 1.0 × s;K FQis the Stern–Volmer fluorescence quenching constant; kq is the bimolecular quenching rate constant; Ka is the binding constant; n is the number of binding sites. See results below. Figure 8 Figure a shows the ITC titration and fitting images of VPPF, and Figure b shows the ITC titration and fitting images of GPF.

[0077] Results Analysis

[0078] Table 1. Fluorescence quenching parameters of GPF and VPPF interactions with α-glucosidase

[0079] PEPTIDES <![CDATA[K FQ ]]> <![CDATA[K q ]]> <![CDATA[K a ]]> n VPPF 213.3 <![CDATA[2.13x10 10 ]]> 210.7 0.9247 GPF 200.4 <![CDATA[2.00x10 10 ]]> 215.8 1.0321

[0080] in, FQ Kq represents the Stern–Volmer quenching constant; Ka represents the bimolecular quenching rate constant; n represents the binding constant; and n represents the number of binding sites.

[0081] Analysis revealed that both peptides exhibited static quenching and could interact with enzymes, altering the microenvironment surrounding the enzyme's intrinsic fluorescent group and enhancing the hydrophobicity of that environment.

[0082] Isothermal titration calorimetry (ITC) analysis

[0083] The thermodynamic interaction between the candidate active peptide and α-glucosidase was investigated using isothermal titration calorimetry (ITC). Before the experiment, the candidate active peptide and α-glucosidase were dissolved separately in the same buffer solution, with the concentration of the candidate active peptide being 5 mg / mL and the concentration of α-glucosidase being 1.5 U / mL.

[0084] The candidate active peptide solution was added to an ITC syringe, and the α-glucosidase solution was added to the sample cell. Titration was performed at 25 °C. During the experiment, the stirring speed was set to 250 rpm, the injection volume was 2 μL per injection, the injection interval was 180 s, and a total of 25 injections were performed. The heat changes generated during the binding of the candidate active peptide and α-glucosidase were recorded in real time during the titration. The same buffer solution used for titrating the candidate active peptide was used as a blank control, and background heat correction was performed on the experimental data.

[0085] The titration data were nonlinearly fitted using the Independent model in NanoAnalyze software to obtain thermodynamic parameters such as binding stoichiometry (n), dissociation constant (Kd), binding enthalpy change (ΔH), and binding entropy change (ΔS), which were used to evaluate the binding characteristics between candidate active peptides and α-glucosidase. The fitting model is as follows:

[0086] (8)

[0087] In the formula, This represents the cumulative heat after the i-th injection; This is the effective volume of the sample cell; This refers to the concentration of α-glucosidase. This represents the total concentration of candidate bioactive peptides. To combine stoichiometric coefficients; The dissociation constant of the candidate active peptide complex with α-glucosidase is given. The binding enthalpy change is used. The binding entropy change (ΔS) was automatically calculated by NanoAnalyze software based on a thermodynamic model; the results are shown in [link to results]. Figure 8 .

[0088] Results Analysis

[0089] Analysis revealed that the binding of the two peptides altered the microenvironment surrounding the enzyme's intrinsic fluorescent group, enhancing local hydrophobicity. Overall, the results indicate that oligopeptides can influence the structure and function of α-glucosidase by forming a complex with it.

[0090] Atomic force microscope (AFM)

[0091] Atomic force microscopy (AFM) was used to observe the changes in surface morphology of the candidate active peptide after interaction with α-glucosidase. The candidate active peptide and α-glucosidase were dissolved in PBS buffer to prepare solutions with a concentration of 1 μg / mL. After mixing in equal volumes, the solutions were incubated at 4 °C for 30 min to promote the full binding of the candidate active peptide and α-glucosidase.

[0092] After incubation, 10 μL of the mixture was dropped onto the surface of freshly peeled mica sheets and allowed to air dry at room temperature under ventilation for 12 h. Subsequently, NanoScope AFM was used for scanning in ScanAsyst mode at a frequency of 0.997 Hz. The obtained AFM images were processed and analyzed using NanoScope Analysis V1.50 software to evaluate the changes in surface morphology and roughness before and after the candidate active peptides bound to α-glucosidase. Simultaneously, morphological parameters such as the average surface roughness (Ra) were measured to quantitatively analyze the changes in surface structure after the interaction of the candidate active peptides with α-glucosidase. The results are shown in [link to results]. Figure 9 .

[0093] Results Analysis

[0094] Both peptides were observed to bind to α-glucosidase after mixing, with VPPF showing stronger binding and GPF showing weaker binding.

[0095] In vitro starch digestion analysis

[0096] The effect of candidate bioactive peptides on starch digestion was evaluated using an in vitro two-enzyme digestion model. Different concentrations of candidate bioactive peptide solutions (0, 50, and 100 mg / mL) were prepared and added to a mixed enzyme solution containing α-amylase (0.0875 U / mL) and α-glucosidase (1.04 U / mL). After thorough mixing, the solutions were pre-incubated at 4 °C for 10 min.

[0097] The digestion reaction was then initiated by adding 2.5 mL of pregelatinized corn starch solution (10 mg / mL). The pregelatinized starch was prepared by heating at 90 °C for 1 h. The digestion system was kept at a constant temperature of 37 °C, and 150 μL of the digest was collected at 0, 3, 6, 9, 15, 30, 45, 60, 90, 120, and 150 min, respectively. The enzymatic reaction was immediately terminated by adding 300 μL of 0.3 mol / L Na₂CO₃.

[0098] After centrifugation at 7300 × g for 5 min, 50 μL of the supernatant was collected, and 1.5 mL of GOD / POD colorimetric working solution was added and thoroughly mixed. The mixture was then incubated in a water bath at 50 ℃ for 20 min, and the absorbance was measured at 510 nm. A standard curve was established using glucose standards, and the glucose concentration in the samples at each time point was calculated based on the regression equation of the standard curve. The actual glucose concentration in the sample was calculated using the following formula:

[0099] (9)

[0100] In the formula, C is the actual glucose concentration in the sample (mg / mL); A is the glucose concentration calculated based on the glucose standard curve (mg / mL); and n is the total dilution factor of the sample.

[0101] Since starch is gradually hydrolyzed by α-amylase and α-glucosidase to eventually produce glucose, the glucose release is converted into the corresponding starch digestibility based on the mass conversion factor (162 / 180) between glucose and starch glucose residues. The starch digestibility at each time point is then calculated using the following formula:

[0102] (10)

[0103] (11)

[0104] In the formula, The measured glucose mass (mg); This represents the amount of starch digested (mg) at time t. Initial starch mass (mg); The starch digestibility (%) at time t.

[0105] To evaluate the effect of candidate bioactive peptides on starch digestion kinetics, the starch digestibility measured at 150 min was used as the apparent final digestibility. The starch digestion process is fitted using a first-order kinetic model, and its expression is as follows:

[0106] (12)

[0107] In the formula, Starch digestibility (%) at time t; The apparent final starch digestibility (%) was measured at 150 min. The first-order digestion rate constant ( ); The digestion time (min) is used. To further analyze the starch digestion kinetics, the formula is... Linearization process:

[0108] (13)

[0109] The kinetic characteristics of starch digestion were analyzed based on the linearization results. This study used 30 min as the kinetic cutoff point to divide the starch digestion process into a rapid digestion phase (0–30 min) and a slow digestion phase (30–150 min), and performed linear fitting for each phase. The results are shown in [link to results]. Figure 10 And calculate the first-order digestion rate constant for the corresponding stage ( , All dynamic parameters were calculated and fitted using Origin 2021; results can be found in [link to results]. Figure 11 .

[0110] Results Analysis

[0111] Compared with the control group, the peptide-treated group exhibited lower starch digestibility (Ct) and a smaller first-order kinetic rate constant (k) throughout the in vitro digestion process, indicating that the peptide can delay starch digestion and glucose release. Among them, VPPF had a stronger delaying effect.

[0112] Oral Starch Tolerance Test (OSTT)

[0113] Since VPPF exhibits superior α-glucosidase inhibitory activity, it was selected as the preferred embodiment for further verification.

[0114] Animal feeding and grouping

[0115] Twenty-four healthy male SPF-grade C57BL / 6J mice (8 weeks old, weighing 20–22 g) were purchased from Spiefer Biotechnology (Beijing) Co., Ltd. The mice were housed in an SPF-grade animal facility under free access to food and water at a temperature of 22 ± 2 ℃, relative humidity of 50%–60%, and a 12-hour light / dark cycle. They underwent a 7-day acclimatization period before the formal experiments. All animal experiments were approved by the Experimental Animal Ethics Committee of Northwest A&F University.

[0116] After the acclimatization period, the mice were randomly divided into three groups of eight mice each (n = 8): a blank control group (Starch + Saline), a positive control group (Starch + Acarbose, 10 mg / kg), and a VPPF group (200 mg / kg).

[0117] Gavage administration

[0118] Mice were fasted for 12 hours prior to the experiment, with free access to water during this period. Subsequently, each group was administered an equal volume of physiological saline, acarbose (10 mg / kg), or VPPF solution (200 mg / kg) by gavage. Fifteen minutes after administration, all groups of mice were uniformly administered pregelatinized corn starch (1 g / kg) by gavage to establish an oral starch tolerance test (OSTT).

[0119] Micro-blood samples were collected at 0, 15, 30, 60, 90, and 120 min after starch gavage using the tail-tip prick method. Blood glucose concentrations were measured using a portable glucometer, and postprandial blood glucose curves were plotted. The area under the curve (AUC) was calculated using the trapezoidal rule. The experimental results are shown below. Figure 12 This study evaluated the regulatory effect of VPPF on postprandial blood glucose levels and glycemic variability. Results are shown in [link to results]. Figure 11 .

[0120] Animal euthanasia

[0121] After the experiment, mice were anesthetized by intraperitoneal injection of 2,2,2-tribromoethanol (0.2 mL / 10 g body weight). After confirming deep anesthesia, they were euthanized by cervical dislocation. All animal experimental procedures strictly followed the ethical guidelines and animal welfare requirements for laboratory animals.

[0122] Results Analysis

[0123] Following starch loading, blood glucose levels in the NC group mice rapidly increased, peaking around 15 minutes. In contrast, the VPPF gavage group showed significantly lower peak and subsequent blood glucose levels, indicating that VPPF can alleviate starch-induced postprandial hyperglycemia. Further AUC analysis showed that the area under the blood glucose curve in the VPPF group was lower than that in the NC group, suggesting that VPPF can reduce overall glucose exposure. Although its regulatory effect is weaker than that of acarbose, it still shows some potential for postprandial blood glucose regulation. Furthermore, there was no significant difference in body weight among the groups, indicating that short-term VPPF treatment did not cause a significant physiological burden.

[0124] The above are merely preferred embodiments of the present invention. It should be noted that, for those skilled in the art, numerous improvements and modifications can be made without departing from the principles of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. The application of a sheep milk casein-derived bioactive peptide in regulating carbohydrate digestion, characterized in that, The active peptides derived from sheep milk casein include GPF and VPPF. The structure of GPF is shown in sequence 1, and the structure of VPPF is shown in sequence 2, wherein Sequence 1: Gly-Pro-Phe, and Sequence 2: Val-Pro-Pro-Phe.

2. The application of the casein-derived bioactive peptide according to claim 1 in regulating carbohydrate digestion, characterized in that, Sheep milk casein-derived bioactive peptides regulate carbohydrate digestion by delaying glucose release during in vitro starch digestion, thereby reducing the rate and degree of starch digestion.

3. The application of the casein-derived bioactive peptide according to claim 1 in regulating carbohydrate digestion, characterized in that, The active peptides derived from sheep milk casein have α-glucosidase inhibitory activity.

4. The application of the casein-derived bioactive peptide according to claim 3 in regulating carbohydrate digestion, characterized in that, The inhibition of α-glucosidase by VPPF exhibits competitive inhibition characteristics, while the inhibition of α-glucosidase by GPF exhibits uncompetitive inhibition characteristics.